Nanobodies Against Influenza and Their Applications in Preparing For Future Pandemics
Simon Hufton, Section Head Molecular Immunology, National Institute for Biological Standard and Control (NIBSC)
Both seasonal and pandemic influenza continue to represent a formidable
public health challenge. The constant evolution of new strains means the
rapid availability of highly specific neutralising monoclonal
antibodies are of considerable interest. Nanobodies are emerging as next
generation antibodies with a number of well documented advantages which
make them highly amenable to applications in the infectious disease
area. This presentation will describe the isolation and characterization
of nanobodies specific for key influenza subtypes including ‘swine flu’
A(H1N1), highly pathogenic avian influenza A(H5N1), highly pathogenic
avian influenza A(H7N9), A(H3N2) and B lineage influenza viruses. The
use of yeast display for mapping their epitopes on hemagglutinin will
also be presented as will their potential applications in preparing for
future influenza pandemics.
|
|